Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026)

Talphera (TLPH) posted Total Non-Current Liabilities of $10.7 million for Q2 2026, up 1.55% on a QoQ basis from $10.5 million in Q1 2026, and up 17.07% year-over-year from $9.1 million in Q2 2025.

Analysis

Talphera (TLPH) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Talphera has reported Total Non-Current Liabilities for 17 years, with the latest figure at $10.7 million in Q2 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 17.07% year-over-year to $10.7 million in Q2 2026; TTM through Jun 2026 was $10.7 million, a 17.07% increase from a year earlier, with the FY2025 full-year figure at $10.3 million, up 12.36% from the prior year.
  • Total Non-Current Liabilities was $10.7 million for Q2 2026 at Talphera, up from $10.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $25.6 million in Q1 2022, with the low at $3.6 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $11.4 million, with a median of $9.8 million recorded in 2024.
  • The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities tumbled 82.08% in 2023, then surged 159.9% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $18.6 million in 2022, then tumbled by 75.71% to $4.5 million in 2023, then surged by 103.32% to $9.2 million in 2024, then grew by 12.36% to $10.3 million in 2025, then rose by 3.68% to $10.7 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $10.7 million (Q2 2026), $10.5 million (Q1 2026), and $10.3 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 378.37 Mn
10 Talphera 92.90 Mn 92.90 Mn - 10.69 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.69 Mn
Mar 31, 2026 10.52 Mn
Dec 31, 2025 10.31 Mn
Sep 30, 2025 9.71 Mn
Jun 30, 2025 9.13 Mn
Mar 31, 2025 8.52 Mn
Dec 31, 2024 9.17 Mn
Sep 30, 2024 9.29 Mn
Jun 30, 2024 9.80 Mn
Mar 31, 2024 9.66 Mn
Dec 31, 2023 4.51 Mn
Sep 30, 2023 3.57 Mn
Jun 30, 2023 4.22 Mn
Mar 31, 2023 10.26 Mn
Dec 31, 2022 18.58 Mn
Sep 30, 2022 19.94 Mn
Jun 30, 2022 22.14 Mn
Mar 31, 2022 25.63 Mn
Dec 31, 2021 28.50 Mn
Sep 30, 2021 29.30 Mn